Early evidence of lymphoproliferative disorder: Post-transplant monitoring of Epstein-Barr infection in adult and pediatric patients

New Microbiologica

Volumn 29, Issue 4, 2006, Pages 231-241

  Gaeta, Aurelia ^a   Nazzari, Cristina ^a   Verzaro, Simona ^a   Latte, Maria Cristina ^a   Fabri, Giovanni ^a   Scateni, Simona ^a   Raggi, Claudia ^a   Lubrano, Riccardo ^a   Mancini, Carlo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

B lymphocyte proliferation; Organ transplantation; Quantitative polymerase chain reaction

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CHILD; EPSTEIN BARR VIRUS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; LYMPHOPROLIFERATIVE DISEASE; METHODOLOGY; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; VIROLOGY; VIRUS INFECTION;

ADULT; CHILD; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION;

HUMAN HERPESVIRUS 4;

EID: 33845703395     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. BAIOCCHI, O.C., COLLEONI, G.W., CABALLERO, O.L., VETTORE, A.L., ANDRADE, A.L., PESTANA, J.O. (2004). Quantification of Epstein-Barr viral load and determination of a cut-off value to predict the risk of post-transplant lymphoproliferative disease in a renal transplant cohort. Haematologica, 89 (3): 366-368.
2. BALDANTI, F., GROSSI, P., FURIONE, M., SIMONCINI, L., SARASINI, A., COMOLI, P., MACCARIO, R., FIOCCHI, R., AND GERNA, G. (2000). High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol. 38 (2): 613-619.
3. BARKHOLT, L.M., DAHL, H., ENBOM, M., LINDE, A. (1996). Epstein-Barr virus DANN in serum after liver transplantation: surveillance of viral activity during treatment with different immunosuppressive agents. Transplant. Int. 9: 439-445.
4. BARR, Y.M., EPSTETN, M.A. (1964). Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet, 1: 702-703.
5. BECK, R., WESTDORP, I., JAHN, G., SCHAFER, H., KANZ, L., EINSELE, H., LIMAYE, A.P. (1999). Detection of Epstein-Barr virus DNA in plasma from patients with lymphoproliferative disease after allogenic bone marrow or peripheral blood stem cell transplantation. J Clin Microbiol. 37: 3430-3431.
6. BERGALLO, M., MERLINO, C., DANIELE, R., SINESI, F., FUMAGALLI, M., PONZI, A.N., CAVALLO, R. (2004). Double-step PCR assay to quantify Epstein-Barr viral load in peripheral blood. Mol Biotechnol. 27 (3): 187-196.
7. CHEN, C.L., WEN, W.N., CHEN, J.Y., HSU, M.M., HSU, H.C. (1993). Detection of Epstein-Barr virus genome in nasopharyngeal carcinoma by in situ DNA hybridization. Intervirol. 36: 91-98.
8. EBPG EXPERT GROUP ON RENAL TRANSPLANTATION. (2002). European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrl Dial Trans 17 Suppl. 4: 31-3, 35-6.
9. GAETA, A., NAZZARI, C., ANGELETTI, S., LAZZARINI, M., MAZZEI, E., MANCINI, C. (1997). Monitoring for cytomegalovirus infection in organ transplant recipients: analysis of pp65 antigen, DNA and late mRNA in peripheral blood leukocytes. J Med Virol. 53: 189-195.
10. GARTNER, B.C., FISCHINGER, J., SHAFER, H., EINSELE, H., ROEMER, K., MULLER-LANTZSCH N. (2002). Epstein-Barr viral load as a tool to diagnose and monitor post-transplant lymphoproliferative disease. Recent results. Cancer Res. 159: 49-54. Review
11. GLASER, S.L., LIN, R.J., STEWART, S.L., AMBINDER, R.F., JARRETT R.F., BROUSSET, P., PALLESEN, G., GULLEY, M.L., KHAN, G., O' GRADY, J., HUMMEL, M., PRECIADO, M.V., KNECHT, H., CHAN, J.K., CLAVIEZ, A. (1997). Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer, 70: 375-382.
12. GOTTSCHALK, S., ROONEY, C.M., HESLOP, H.E. (2004). Post-transplant lymphoproliferative disorders. Ann Rev Med. 56: 29-44.
13. GREEN, M. (2001). Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant. 1: 103-108.
14. HUMMEL, M., ANAGNOSTOPOULOS, I., KORBJUHN, P., STEIN, H. (1995). Epstein-Barr virus in B cell non Hodgkin's lymphomas: unexpected infection patterns and different infection incidence in low- and high-grade types. J Pathol 175: 263-271.
15. IEZZONI, J.C., GAFFEY, M.J., WEISS, L.M. (1995). The role of Epstein-Barr virus in lymphoepithelioma-like carcinomas. Am J Clin Pathol. 103: 308-315.
16. IMAI, S., KOIZUMI, S., SUGIURA, M., TOKUNAGA, M., UEMURA, Y., YAMAMOTO, N., TANAKA, S., SATO, E., OSATO, T. (1994). Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci USA, 91: 9131-9135.
17. JANG, J., TAO, Q., FLINN, IW., MURRAY, P.G., POST, L.E., MA, M., PIANTADOSI, S., CALINGIURI, M.A., AMBINDER, R.F. (2000). Characterization of Epstein-Barr virus-infected B cells in patients with post transplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood, 96 (13): 4055-4063.
18. KENNETH, G.L., BURTON, R.L., ZIMMERMAN, S.E., WANG, J., CORNETTA, K.G., ROBERTSON, K.A., LEE, C.H., EMANUEL, DJ. (1998). Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-Induced lymphoproliferative disease after stem cell transplantation. Blood, 91: 3654-3661.
19. KIMURA, H., MORITA, M., YABUTA, Y., KUZUSHIMA, K., KATO, K., KOJIMA, S., MATZUYAMA, T., MORISHIMA, T. (1999). Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol. 132-136.
20. KNOWLES, D.M., CESARMAN, E., CHADBURN, A. (1995). Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of post transplantation lymphoproliferative disorders. Blood, 85: 552-565.
21. KOPF, S., TONSHOFF, B. (2004). Surveillance of Epstein-Barr virus infection as a risk factor for post-transplant lymphoproliferative disorder in pediatric renal transplant recipients. Pediatr. Nephrol. 19: 365-368.
22. KWOK, S. (1990). Procedures to minimize PCR-product carry-over. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, editors. PCR protocols. A guide to methods and applications. San Diego, CA: Academic Press. 142-145.
23. LAROCHE, C., DROUET, E.B., BROUSSET, P., PAIN, C., BOIBIEUX, A., BIRON, F., ICART, J., DENOYEL, G.A,, NIVELEAU, A. (1995). Measurement by the polymerase chain reaction of the Epstein-Barr virus load in infectious mononucleosis and AIDS-related non-Hodgkin's lymphomas. J Med Virol. 46 (1): 66-74.
24. LEVINE, A.M. (1992). Acquired immunodeficiency syndrome-related lymphoma. Blood, 80 (1): 8-20.
25. LEVINE, A.M. (1994). Lymphoma complicating immunodeficiency disorders. Ann Oncol. 5 - suppl 2: 29-35.
26. LIMAYE, A.P., HUANG, M.L., ATIENZA, E.E., FERREMBERG, J.M., AND COREY, L. (1999). Detection of Epstein-Barr Virus DNA in sera from transplanted recipients with lymphoproliferative disorders. J Clin Microbiol. 37 (4): 1113-1116.
27. MORRISON, V., DUNN, D., MANIVEL, J., GAJL-PECZALSKA, K., PETERSON, B. (1994). Clinical characteristics of post-transplant lymphoproliferative disorders. Am. J. Med. 97 (1): 14-24.
28. NAZZARI, C., GAETA, A., LAZZARINI, M., DELLI CASTELLI, T., MANCINI, C. (2000). Multiplex polymerase chain reaction for the evaluation of cytomegalovirus DNA load in organ transplant recipients. J Med Virol. 61: 251-258.
29. PAYA, C.V., FUNG, J.J., NALESNIK, M.A. 1999. EBV induced post-transplant lymphoproliferative disorders. Transplantation, 68: 1517-1525.
30. PENN, I. (1990). Cancers complicating organ transplantation. N. Engl. J. Med. 323 (25): 1767-1769.
31. RIDDLER, S.A., BEINING, M.C., MCKNIGHT, J.L.C. (1994). Increased levels of circulating Epstein-Barr virus-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of post-transplants lymphoproliferative disease in solid-organ transplant recipients. Blood, 84: 972-984.
32. RODNEY, C.M., LOFTIN, S.K., HOLLADAY, M.S,, BRENNER, M.K., KRANCE, R.A. (1995). Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br. J. Haematol. 89: 98-103.
33. ROWE, D.T., QU, L., REYES, J. (1997). Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant recipients with lymphoproliferative disorders. J Clin Microbiol. 35: 1612-1615.
34. SAVOIE, A., PERPETE, C., CARPENTIER, L., JONCAS, J., AND ALFIERI, C. (1994). Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood, 83 (9): 2715-2722.
35. SCHEENSTRA, R., VERSCHUUREN, E.A.M., DE HAAN, A., SLOOFF, M.J.H., THE, T.H., BIJLEVELED, C.M.A., VERKADE, H.J. (2004). The value of prospective monitoring of Epstein-Barr virus Dna in blood samples of pediatric liver transplant recipients. Transplant Infect Dis. 6: 15-23.
36. SHAPIRO, R.S., MCCLAIN, K., FRIZZERA, G. (1988). Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood, 71: 1234-1243.
37. SHIPP, M.A., MAUK, P.M., HARRIS, N.L. (1997). Non-Hodgkin's lymphomas. In: De Vita V.T., Hellman S., Rosenberg S.A., editors. Cancer principles e practice of oncology-Philadelphia New York: Lippincott-Raven 2165-2213.
38. SHROFF, R., REES, L. (2004). The post-transplant lymphoproliferative disorder. Pediatr. Nephrol. 19: 369-377.
39. SMETS, F. (2002). Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation, 73: 1603-1610.
40. STARZL, T.E., NALESNIK, M.A., PORTER, K.A., HO, M., IWATSUKI, S., GRIFFITH, B.P., ROSENTHAL, J.T., HAKALA, T.R., SHAW, B.W. JR, HARDESTY, R.L. (1984). Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet, 1 (8377): 583-587.
41. STEVENS, S.J.C., VERSCHUUREN, E.A.M., PRONK, I., VAN DER BIJ, W., HARMSEN, M.C., THE, T.H., MEIJER, C.J.L.M., VAN DEN BRULE, A.J.C., MIDDELDORP, J.M. (2001). Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood, 97 (5): 1165-1171.
42. SWINNEN, L., COSTANZO-NORDIN, M.R., FISHER, S.G., O' SULLIVAN, E.J., JOHNSON, M.R., HEROUX, A.L., DIZIKES, G.J., PIFARRE, R., FISHER, R.I. (1990). Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med. 323 (25): 1723-1728.
43. WALKER, R.C., PAYA, C.V., MARSHALL W.F. (1995). Pretransplantation seronegative Epstein-Barr virus status in the primary risk factor for post-transplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant. 14: 214-221.
44. WILKINSON, A.H., SMITH, J.L., HUNSICKER, L.G. (1989). Increased frequency of post-transplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation, 47 (2): 293-296.
45. YOUNG, L.S., ALFIERI, C., HENNESSY, K. (1989). Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med. 321: 1080-1085.
46. ZILZ, N.D., OLSON, L.J., MC GREGOR, G., (2001). Treatment of Post-Transplant Lymphoproliferative Disorder with Monoclonal CD20 Antibody (Rituximab) After Heart Transplantation. J Heart Lung Transplantat, 20 (7): 770-772.